UNASSIGNED: This review summarizes the state of knowledge relating to the pharmacokinetics of dabigatran (factor IIa/thrombin inhibitor) and apixaban, edoxaban and rivaroxaban (factor Xa) inhibitors. We focus on pharmacokinetic differences between the drugs which may have clinically significant implications.
UNASSIGNED: Patient-centered care necessitates a careful consideration of the pharmacokinetic and pharmacodynamic differences between DOACs, and how these relate to individual patient circumstances. Prescribers should be aware of the potential for pharmacokinetic drug interactions with DOACs which may influence prescribing decisions in patients with multiple comorbidities. In order to give an appropriate dose of DOAC drugs, accurate estimation of renal function using the Cockcroft-Gault formula using actual body weight is necessary. An increasing body of evidence supports the use of DOACs in patients who are obese, and this is becoming more routine in clinical practice.
■这篇综述总结了与达比加群(因子IIa/凝血酶抑制剂)和阿哌沙班的药代动力学有关的知识状况,依度沙班和利伐沙班(因子Xa)抑制剂。我们关注药物之间的药代动力学差异,这些差异可能具有临床意义。
■以患者为中心的护理需要仔细考虑DOAC之间的药代动力学和药效学差异,以及这些与个体患者情况的关系。处方者应该意识到与DOAC的药代动力学药物相互作用的潜力,这可能会影响患有多种合并症的患者的处方决策。为了给予适当剂量的DOAC药物,使用Cockcroft-Gault公式使用实际体重准确估计肾功能是必要的。越来越多的证据支持在肥胖患者中使用DOAC,这在临床实践中变得越来越常规。